Source author record

Neal G. Ravindra

Neal G. Ravindra appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
3topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2020arXiv

Disease State Prediction From Single-Cell Data Using Graph Attention Networks

Single-cell RNA sequencing (scRNA-seq) has revolutionized biological discovery, providing an unbiased picture of cellular heterogeneity in tissues. While scRNA-seq has been used extensively to provide insight into both healthy systems and diseases, it has not been used for disease prediction or diagnostics. Graph Attention Networks (GAT) have proven to be versatile for a wide range of tasks by learning from both original features and graph structures. Here we present a graph attention model for predicting disease state from single-cell data on a large dataset of Multiple Sclerosis (MS) patients. MS is a disease of the central nervous system that can be difficult to diagnose. We train our model on single-cell data obtained from blood and cerebrospinal fluid (CSF) for a cohort of seven MS patients and six healthy adults (HA), resulting in 66,667 individual cells. We achieve 92 % accuracy in predicting MS, outperforming other state-of-the-art methods such as a graph convolutional network and a random forest classifier. Further, we use the learned graph attention model to get insight into the features (cell types and genes) that are important for this prediction. The graph attention model also allow us to infer a new feature space for the cells that emphasizes the differences between the two conditions. Finally we use the attention weights to learn a new low-dimensional embedding that can be visualized. To the best of our knowledge, this is the first effort to use graph attention, and deep learning in general, to predict disease state from single-cell data. We envision applying this method to single-cell data for other diseases.

preprint2020arXiv

Self-supervised edge features for improved Graph Neural Network training

Graph Neural Networks (GNN) have been extensively used to extract meaningful representations from graph structured data and to perform predictive tasks such as node classification and link prediction. In recent years, there has been a lot of work incorporating edge features along with node features for prediction tasks. One of the main difficulties in using edge features is that they are often handcrafted, hard to get, specific to a particular domain, and may contain redundant information. In this work, we present a framework for creating new edge features, applicable to any domain, via a combination of self-supervised and unsupervised learning. In addition to this, we use Forman-Ricci curvature as an additional edge feature to encapsulate the local geometry of the graph. We then encode our edge features via a Set Transformer and combine them with node features extracted from popular GNN architectures for node classification in an end-to-end training scheme. We validate our work on three biological datasets comprising of single-cell RNA sequencing data of neurological disease, \textit{in vitro} SARS-CoV-2 infection, and human COVID-19 patients. We demonstrate that our method achieves better performance on node classification tasks over baseline Graph Attention Network (GAT) and Graph Convolutional Network (GCN) models. Furthermore, given the attention mechanism on edge and node features, we are able to interpret the cell types and genes that determine the course and severity of COVID-19, contributing to a growing list of potential disease biomarkers and therapeutic targets.